Objective: To validate a brief and reliable epilepsy-specific, health-related quality of life (HRQOL) measure in children with various seizure types, treatments, and demographic characteristics. Methods: This national validation study was conducted across five epilepsy centers in the United States. Youth 5-18 years and caregivers of youth 2-18 years diagnosed with epilepsy completed the PedsQL Epilepsy Module and additional questionnaires to establish reliability and validity of the epilepsy-specific HRQOL instrument. Demographic and medical data were collected through chart reviews. Factor analysis was conducted, and internal consistency (Cronbach's alphas), test-retest reliability, and construct validity were assessed. Results: Questionnaires were analyzed from 430 children with epilepsy (M age = 9.9 years; range 2-18 years; 46% female; 62% white: non-Hispanic; 76% monotherapy, 54% active seizures) and their caregivers. The final PedsQL Epilepsy Module is a 29-item measure with five subscales (i.e., Impact, Cognitive, Sleep, Executive Functioning, and Mood/Behavior) with parallel child and caregiver reports. Internal consistency coefficients ranged from 0.70-0.94. Construct validity and convergence was demonstrated in several ways, including strong relationships with seizure outcomes, antiepileptic drug (AED) side effects, and well-established measures of executive, cognitive, and emotional/behavioral functioning. Significance: The PedsQL Epilepsy Module is a reliable measure of HRQOL with strong evidence of its validity across the epilepsy spectrum in both clinical and research settings.
Epilepsy affects 1% of children younger than 16 years of age. 1 The goal of treatment is to control seizures, minimize side effects, and optimize health-related quality of life (HRQOL), 2 an important patient-reported outcome assessing multiple domains (e.g., physical, emotional, and social). [3] [4] [5] A significant need exists for HRQOL measures that are developmentally sensitive, reliable, and practical across the entire spectrum of children with epilepsy (e.g., typical and atypical development). Existing pediatric epilepsy-specific HRQOL measures (e.g., Quality of Life in Epilepsy-Adolescents [QOLIE-AD-48], 6 Quality of Life in Childhood Epilepsy [QOLCE] 7, 8 ) have weaknesses that compromise their clinical utility, including being quite lengthy (48-79 items), lack of parallel caregiver and childreport forms, and lack of inclusion of those with learning/ developmental disabilities during instrument development. The development of a reliable and clinically useful epilepsy-specific HRQOL measure would enable healthcare providers to ascertain the impact of epilepsy and its treatments on the daily functioning of youth with epilepsy at point of care. This would allow providers to better hone medical and psychological interventions to optimize HRQOL and reduce epilepsy morbidity. The PedsQL Epilepsy Module was developed using a standardized, iterative process 9 and assesses youth 2-18 years, with both self-report (5-to 18-years-old) and parent-report (2-to18-years-old). The PedsQL has a generic core that assesses generic HRQOL, including Physical, Emotional, Social, and School functioning. 3, 4 In addition, many disease-specific modules (e.g., sickle cell disease and gastrointestinal disorders) [10] [11] [12] have been developed to assess aspects most salient to the disease. The core and disease-specific modules can be used together or individually depending on the needs of the researcher or clinician. The current study is a national validation of the PedsQL Epilepsy Module across five diverse sites. Expectations for the PedsQL Epilepsy Module were the following: (1) six internally consistent factors; (2) good test-retest reliability; (3) strong associations with antiepileptic drug (AED) side effects, emotional/behavioral, cognitive, and executive functioning; and (4) detection of differences between important clinical groups (e.g., absence/presence of seizures, mono versus polytherapy, developmental/learning disorders versus not). Secondary aims included calculating minimal clinically important differences (MCIDs) and examining measurement invariance on the PedsQL Epilepsy Module.
Methods

Participants
Children 5-18 years of age and caregivers of children ages 2-18 years of age diagnosed with epilepsy were recruited from five pediatric tertiary care centers (Cincinnati Children ' (1) ability to read English due to questionnaires only being validated in English, and (2) no other chronic medical condition (e.g., diabetes), except for allergies and neurobehavioral comorbidities.
Procedure
Participants were recruited by research personnel across neurology settings (e.g., outpatient clinic, inpatient, and epilepsy monitoring unit). Caregiver consent and child assent were obtained. Data were collected between August 2014 and March 2016. Participants completed questionnaires based on their age and recruitment site. Children considered cognitively impaired by caregivers or healthcare providers did not complete questionnaires. Medical chart reviews were conducted by research staff. CCHMC, CHOC, and MUSC administered all questionnaires, whereas CCHCS and UW completed a shorter validation battery (i.e., PedsQL Epilepsy Module, Generic Core Scales, Cognitive Functioning Scale, and Family Information Form) to increase sample size for the factor analyses. Children and caregivers were each reimbursed with gift cards. A subset of participants at three sites completed the PedsQL Epilepsy Module and interval history form 2-4 weeks after enrollment to assess test-retest reliability. The study was approved by each site's institutional review board.
Measures
The PedsQL Epilepsy Module has parallel parent and child versions for ages 5-18 (Young Child, Child, and Teen subgroups), and parent report only for Toddlers ages 2-4. The original measure ranged from 26 to 33 items and assessed six domains based on focus group/cognitive interviews 9 (i.e., restrictions, seizure management, social, sleep/ fatigue, cognitive/executive functioning, and mood/behavior). The format, directions, time frame, response options, scoring, and syntax are similar to the PedsQL 4.0 Generic Core Scales. 3, 4 Domains and items are generally consistent across all versions but adjusted for language (i.e., simplified for younger children) and content (e.g., teen version includes driving as an example). Each domain assesses the extent to which epilepsy and/or its treatments affects child HRQOL by asking how much of a problem the item has been in the past month on a 5-point Likert scale (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = always a problem). Responses are reverse scored and linearly transformed to a 0-100 scale, with higher scores reflecting better HRQOL.
The PedsQL, a 23-item generic HRQOL measure for parents of children between 2 and 18 years of age and for children ages 5 and 18, assesses Physical, Emotional, Social, and School functioning. 16 ) is a 19-item measure of AED side effects in children ages 2-18 with epilepsy. Items assess the severity of neurologic, behavioral, cognitive, weight, and motor side effects. Items are summed to obtain a total side-effects score. The measure has strong psychometrics. 16 The PedsQL Family Information Form/Background Questionnaire was completed by caregivers providing general information about the child's age, caregiver work history, school absences, hospitalizations, and comorbid diagnoses. The Revised Duncan score was calculated for each family based on caregiver occupation and serves as a measure of socioeconomic status (SES), 17 with higher scores indicating higher SES. A medical chart review gathered data regarding epilepsy type, 18 treatment, seizure frequency in the past 3 months, and medical and psychosocial comorbidities. An Interval History Form was also completed to ensure patients were stable (e.g., no seizures or side effects) during the test-retest phase.
Statistical and data analyses
Descriptive statistics were used to characterize demographic, medical, and HRQOL. Floor and ceiling effects were calculated by examining the proportion of responses on the scales that were at zero or 100, respectively. Proportions <15% suggests the absence of significant floor or ceiling effects. 19 
Factor analysis
An exploratory factor analysis (EFA) with geomin rotation 20 was conducted to examine whether the 33 items measured one or more constructs. The possibility of 1 to 8 factors accounting for the covariation among the 33 items were tested, hypothesizing 6 factors and a total score. 9 Several criteria were used to determine which factor structure to retain: (1) eigenvalues >1, 21 (2) no negative residual item variances, and (3) root mean square error of approximation (RMSEA) <0.05 and standard root mean square residual (SRMR) <0.08. Items that were not relevant to particular age versions were considered missing. Confirmatory factor analyses (CFAs) were conducted to examine whether the covariance among all the item responses was accounted for by a single HRQOL score and 6 hypothesized subscales, or an alternate model based on the EFA results. Goodness of fit was based on empirically supported indices 22 : RMSEA values <0.05, comparative fit index (CFI) and Tucker-Lewis Index (TLI) values >0.95, and SRMR values <0.08. Analyses used Mplus version 7.2 23 and its weighted least squares with mean and variance adjustment estimator. A nested model was used to account for the correlations among the parent-child dyads. 24 Cronbach's alpha 25 assessed reliability for parent and child PedsQL Epilepsy Module subscales. Test-retest reliability and agreement between parent-child dyads were assessed using intraclass correlations in SPSS version 23. Independent t-tests examined group differences for sex, seizure absence/presence in the last 3 months, monotherapy versus polytherapy, and children with a developmental/ learning disorder versus not. Pearson correlations were used to examine the relationship between HRQOL and side effects and SES.
MCIDs, which refer to the smallest clinically important change in scores, were calculated using one standard error of measurement (SEM), which has been well-supported in the literature 27, 28 : SEM = SD√[1-a], SD = standard deviation of mean PedsQL Epilepsy Module scores for each scale (0-100 scores); a = scale reliability. 29 Finally, we examined invariance for the presence or absence of developmental/learning disorders, sex, presence or absence of seizures, and monotherapy versus polytherapy using a multiple group confirmatory factor analysis in Mplus. Measurement invariance refers to stability in the psychometric properties of a measure across populations or occasions. 30 When studying differences in quality of life between groups, differences observed on the measure of that construct should reflect actual difference between the groups in the construct itself. If invariance holds across groups, one can be confident that the observed differences are due to differences between groups versus changes in the psychometric properties of the measure. Invariance was established in the following three steps: (1) configural invariance is demonstrated when the pattern of factor loadings is found to be similar across groups; (2) metric invariance is found when the relationships between the indicators and the construct (e.g., the loadings) are equivalent for each group; and (3) scalar invariance holds if all the loadings, as well as all the thresholds, are equivalent for each group. More restrictive models were compared to less restrictive models by calculating the differences in CFI and RMSEA (ΔCFI and ΔRMSEA). A ΔCFI > 0.01 or a ΔRMSEA > 0.015 would indicate the more restrictive model was a poorer fit.
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Results
Participants
Demographic and medical information for youth with epilepsy (n = 263) and their caregivers (n = 394) can be found in Table 1 .
Exploratory and confirmatory factor analyses
The EFA indicated that four-, five-, and six-factor solutions explained the data well (parent-report: RMSEA ranged from 0.07-0.05 and SRMR ranged from 0.03-0.04; childreport: RMSEA ranged from 0.04-0.03 and SMRM ranged from 0.05-0.04). Eigenvalues suggested a five-factor solution for parent-report and a six-factor solution for childreport. Given our a priori hypotheses of six subscales, we first examined the six-factor solution. The six-factor solution had several problems, including high cross loadings and stronger loadings on nonspecified factors; thus the sixfactor solution was not pursued. A four-factor solution was also tried but had problems (e.g., several items did not load on any factor or small cross loadings). A five-factor solution was tested from the EFA and determined to have the ideal factor solution based on the original hypothetical model. Notably, items from the "restrictions," "seizure management," and "social" subscales loaded onto a single factor (i.e., "impact" scale), with the exception of "I am teased or bullied," which was dropped, leaving a 10-item scale. The next two factors from the EFA comprised six of the original nine cognitive/executive function items to create a "cognitive" scale, whereas the other three items combined with four "behavior" items to create an "executive function" subscale. The original three sleep subscale items were retained on a single factor. Finally, the last factor consisted of five items, reflecting "mood/behavior" from the original "mood/ behavior" subscale. One item "I worry about having seizures, treatment side effects, and/or blood draws" did not strongly load with any particular factor, likely due to the compound nature of the question, and was dropped. The CFA was conducted to determine whether eliminating the cross loadings would reveal problematic items or fit in the five-factor solution. The parent and child data were initially combined in a single model, accounting for correlations among dyads. The final factor structure was examined separately for each respondent. The five-factor solution fit well in the combined data (RMSEA = 0.06, CFI = 0.91, TLI = 0.91); however, two of the items ("I need to eat or exercise differently because of my epilepsy," "I have had personality changes") were dropped due to lack of scale relevance or concerns about future language translations. The final iteration was a 29-item measure with five factors that fit well in the combined dyadic data (RMSEA = 0.06, CFI = 0.91, TLI = 0.91), as well as the parent-report data (RMSEA = 0.09, CFI = 0.95, TLI = 0.95), and child-report data (RMSEA = 0.05, CFI = 0.95, TLI = 0.95; Table 2 for final parameter estimates).
Final PedsQL epilepsy module
The PedsQL Epilepsy Module is a 29-item measure with five scales: Impact, Cognitive, Sleep, Executive Function, and Mood/Behavior. There is no total score for this measure because evidence of an overall "HRQOL" summary factor was not supported by the data. The Impact scale (nine items) assesses how epilepsy interferes with daily activities, interacting with peers, independence, and increased disease burden due to treatment. The Cognitive Scale (six items) assesses memory, ability to learn new materials, schoolrelated difficulties, and reading difficulties. The Sleep Scale (three items) assesses fatigue and sleep difficulties. The Executive Function Scale (six items) assesses organization, task initiation, impulsivity, and inattention. The Mood/ Behavior Scale (five items) assesses feelings of anger, sadness, worries, and frustration tolerance. Factor loadings and descriptive data are presented in Table 2 . No ceiling or floor effects were identified for the PedsQL Epilepsy Module subscales. The highest ceiling and floor effects were for the parent-report Cognitive Scale at 5.1% and 13.2%, respectively. Flesch-Kincaid grade readability statistics indicated a Grade 2-3 reading level.
Reliability
Internal consistency coefficients for each scale were strong (see Table 3 ), with the lowest alpha for the Sleep Scale in 2-to 4-year-old children. The Sleep Scale is not scored for toddlers as a result but can be used for clinical purposes to further inquire about sleep difficulties. Test-retest reliability was calculated for 75 participants and 102 caregivers. Average time between test-retest was 17.3 AE 7.6 days. Test-retest reliability was strong, ranging from 0.59 to 0.83 (see Table 2 ). Intraclass correlations for caregiver-child dyads (n = 260) were also excellent, ranging from 0.45 to 0.60 (see Table 4 ).
Validity
Strong correlations were found between similar scales, especially for parent reports (see Table 4 ). Total side effects were significantly correlated with all parent-report (r's = À0.30 for Mood to À0.54 Impact) and child-report (r's = À0.25 for Mood to À0.40 Impact) PedsQL Epilepsy Module scales. As AED side effects increased, HRQOL decreased. No significant correlations were found with PedsQL Epilepsy modules and SES, except for parent report of Mood/Behavior (r = 0.12, p < 0.05) and child report of Cognitive (r = 0.15, p < 0.05), with higher SES being associated with better mood/behavior and cognitive functioning.
Children with active seizures in the past 3 months had significantly lower parent-and child-reported PedsQL Epilepsy Module scores compared to children who were seizure free (see Fig. 1A ). Children on monotherapy had significantly higher HRQOL compared to children on polytherapy across both parent-and child-reported PedsQL Epilepsy Module scales (see Fig. 1B ). The presence of a developmental/learning disorder had a significant negative impact on all subscales of the PedsQL Epilepsy Module scales (see Fig. 1C ) compared to children without these disorders. Sex differences were only found for the parent-reported Executive Functioning scale and child-reported Mood/Behavior scale (See Fig. 1D ). Specifically, females were reported to have higher executive functioning (t(391) = À3.3, p < 0.001) and lower mood/behavior (t(259) = 3.45, p < 0.001).
Minimal clinically important difference (MCID)
Standard errors of measurement ranged from 7.59 (Cognitive) to 12.61 (Sleep) for parent-report scales and 8.44 (Impact) to 14.68 (Sleep) for child-report scales (See Table 3 ).
Measurement invariance
We found evidence for scalar invariance across sex (i.e., the structure and pattern of loadings and thresholds was equal across males and females), configural model fit: v² (734) = 979.44, p < 0.001, CFI = 0.955, RMSEA = 0.050; configural versus metric fit difference: ΔCFI = 0.004, ΔRMSEA = 0.002; and metric versus scalar fit difference: ΔCFI = 0.001, ΔRMSEA = 0.004. We also found evidence for scalar invariance across the presence versus absence of learning or developmental disorders (i.e., the structure and pattern of loadings and thresholds were equal across those with and without learning or developmental disorders), configural model fit: v² (734) = 990.13, p < 0.001, CFI = 0.940, RMSEA = 0.053; configural versus metric fit difference: ΔCFI = 0.002, ΔRMSEA = 0.003; and metric versus scalar fit difference: ΔCFI = 0.003, ΔRMSEA = 0.002. Notably, we were unable to examine invariance for the presence/absence of seizures or mono/polytherapy due to the lack of variability in the item-response patterns. 
Discussion
The results of the current study support the PedsQL Epilepsy Module as a reliable and valid measure of epilepsyspecific HRQOL across the epilepsy spectrum. The PedsQL Epilepsy Module has excellent psychometric properties, including good internal consistency among subscales, testretest reliability, strong construct and convergent validity, and strong correlations between child and parent versions. In addition, we found evidence for measurement invariance across sex and the presence versus absence of developmental/learning disorders. A primary strength of the study is the large, diverse, and heterogeneous sample used to both create and provide evidence of the validity of the measure. This brief instrument is appropriate for youth across the epilepsy spectrum and can be easily embedded in both research and clinical practice. The accessibility, simple and rapid scoring, and grade 2-3 readability of the instrument lends itself to use in clinical encounters by any epilepsy team member.
Similar to prior literature, [33] [34] [35] patients with active seizures, more side effects, and/or on polytherapy had worse HRQOL. Children with developmental/ learning disorders also reported worse HRQOL compared to children without these disorders. Sex differences were only found for two PedsQL Epilepsy Module scales. Parents of boys reported higher executive dysfunction and girls themselves endorsed more internalizing problems, which is consistent with the broader literature. 36, 37 These findings support the construct validity of the PedsQL Epilepsy Module by demonstrating that the measure can distinguish between clinically meaningful groups. Finally, moderate agreement was found between parent-child dyads, with the Sleep and Mood/ Behavior subscales having the lowest agreement. This is likely due to caregivers lacking awareness about more internal states compared to observable domains. 38 The PedsQL Epilepsy Module composed of five scales that capture unique aspects of the epilepsy experience and are consistent with other epilepsy-specific HRQOL measures. [6] [7] [8] The Impact subscale measures how epilepsy can restrict daily activities, interfere with developmentally expected independence, and delay milestones. This allows providers to understand the perceived burden of epilepsy and provide guidance about the balance between medically indicated restrictions versus overprotection that can lead to excessive functional disability. The Cognitive and Executive Functioning scales represent two common areas that can cause significant impairment across home and school settings. Deficits can persist despite seizure control, extend into adulthood, 39 and interfere with selfmanagement (e.g., remembering to take AEDs). Similarly, the Mood/Behavior scale taps into common internalizing and externalizing comorbidities [37] [38] [39] reported in youth with epilepsy. The Mood/Behavior Scale can be used as a screener for psychosocial comorbidities. The 
